Research, News and Events
James is involved in a wide range of academic research, currently focussing his interests on vitreoretinal surgery, age-related macular degeneration, artificial intelligence and the exploration or ocular biomarkers for neurological disease. He is also actively involved in educational meetings and working with the leading UK eye charities.
39
Published Papers
18
Awards and Prizes
- View All
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
August 2024
RNIB Charity Age-Related Macular Degeneration Factsheet
Mr. Neffendorf was invited by the RNIB charity to review and update their factsheet on age-related macular deneration (AMD) and anti-vascular endothelial growth factor (anti-VEGF) treatment. These are medications that are used to treat wet AMD. The factsheet is now available at https://www.rnib.org.uk/your-eyes/eye-conditions-az/anti-vegf-treatment/. The webpage also contains a video featuring Mr. Neffendorf and one of his AMD patients that was produced 10 years ago.
Mr James E. Neffendorf and RNIB
June 2024
Hjalmar Schiøtz Vitreoretinal Meeting - Oslo
Mr. Neffendorf was invited to attend this new retinal surgical meeting in Oslo, Norway. It brought together Vitreoretinal Surgeons from throughout Europe to share research, innovation and surgical technique.
Mr James E. Neffendorf and Professor Goran Petrovski
May 2024
Invited Judge - Théa Pharmaceuticals 'Lessons Learned Symposium'
James was invited to judge the presentations of London Ophthalmic Surgical Trainees at the Théa presentation evening. The quality of presentation submissions was high, with a focus on safety and learning from surgical mistakes. The winning presentation was on the subject of vision loss due to inflammation inside the eye.
Mr James E. Neffendorf and Théa Pharmaceuticals
December 2023
The implantable miniature telescope ( IMT ) new developments: The US and UK experience
The Implantable Miniature Telescope (IMT) is a viable option for patients afflicted with decreased vision in both eyes (20/160 to 20/800) from the advanced form of dry age‐related macular degeneration. It has a 21‐year history of being both safe and effective. The IMT uses a Galilean telescope design that utilizes wide‐angle quartz micro‐optics whe...
Marc H. Levy David Keegan James Emil Neffendorf